Noninjection routes for immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 3, 2003, Pages 437-448

  Canonica, Giorgio Walter ^a,b   Passalacqua, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b DIMI   (Italy)

Author keywords

Allergen immunotherapy; Local nasal immunotherapy; Noninjection routes; Sublingual immunotherapy

Indexed keywords

ALLERGEN; IMMUNOLOGIC AGENT;

ALLERGIC REACTION; ANTIGEN SPECIFICITY; BRONCHUS MUCOSA; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; NOSE MUCOSA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS;

EID: 0037340480     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.129     Document Type: Review

References (137)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911:i:1572-3.
2. Curtis HH. The immunizing cure of hayfever. Med News (NY) 1900;77:16-8.
3. Black JH. The oral administration of pollen. J Lab Clin Med 1927;12:1156.
4. Black JH. The oral administration of pollen: clinical report. J Lab Clin Med 1928;13:709.
5. Herxeimer H. Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol 1951;40:40-57.
6. Herxeimer H, Prior EN. Further observations in induced asthma and bronchial hyposensitization. Int Arch Allergy Appl Immunol 1952;3:159-61.
7. Metha SB, Smith JM. Nasal hyposensitization and hayfever. Clin Allergy 1975;5:279-84.
8. Taylor G, Shivalkar PR. Local nasal desensitization in allergic rhinitis. Clin Allergy 1972;2:125-6.
9. Rebien W, Wahn U, Puttonen E, Maasch HG. Comparative study of immunological and clinical efficacy of oral and subcutaneous hyposensitization. Allergologie 1980;3:101-9.
10. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983;38:561-4.
11. Urbanek R, Gehl R. Wirksaimkeit oral hiposensibilisierung bei hausstabmilbenallergie. Monatssch Kinderheilkd 1982;130:150-2.
12. Committee on the safety of medicines. CSM update: desensitizing vaccines. Br Med J 1986;293:948.
13. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987;79:660-77.
14. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TAE. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993;92:6-15.
15. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(suppl 1):47-55.
16. Malling HJ, Weeke B, editors. EAACI Immunotherapy position paper. Allergy 1993;53(Suppl 44):6-30.
17. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-91.
18. Bousquet J, Lockey R, Malling HJ, editors. World Health Organization position paper: allergen immunotherapy - therapeutical vaccines for allergic diseases. Allergy 1998;53(suppl):?.
19. Malling HJ, editor. EAACI position paper on local immunotherapy. Allergy 1998;53:933.
20. Bousquet J, Van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S240-S245.
21. Laissue JA, Chappuis BB, Muller C, Reubi JC, Gebbers JO. The intestinal immune system and its relation to disease. Dig Dis 1993;11:298-312.
22. Cooper PJ, Darbyshire, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14:541-50.
23. Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients: an efficacy study in oral hyposensitization. Allergy 1985;40:321-35.
24. Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. Allergy 1986;41:271-9.
25. Taudorf E, Laursen CL, Lanner A, et al. Oral immunotherapy to birch pollen hay fever. J Allergy Clin Immunol 1987;80:153-61.
26. Mosbech H, Dreborg S, Madsenn F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients: a one year double blind placebo controlled study. Allergy 1987:42:451-5.
27. Giovane A, Bardare M, Passalacqua G, et al. A three year double blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in pediatric patients. Clin Exp Allergy 1994;24:53-9.
28. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:61-7.
29. Van Deusen MA, Angelini BL, Cordoro KM, Seiler BA, Wood L, Skoner DP. Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol 1997;78:573-80.
30. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed in a novel encapsulated preparation: a double blind study. J Allergy Clin Immunol 1997;100:30-8.
31. Taudorf E, Lanner A, Laursen L, et al. Specific IgG IgE and IgA antibody response to oral immunotherapy in birch pollenosis. J Allergy Clin Immunol 1989;83:589-94.
32. Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991;87:721-8.
33. Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: a double blind study. J Investig Allergol Clin Immunol 1992;2:59-67.
34. Holt PG, Sedgwick JD. Suppression of IgE response following antigen inhalation: a natural homeostatic mechanism which limits sensitizations to aeroallergens. Immunol Today 1987;8:14-5.
35. Holt PG, McMenamin C. Defense against allergic sensitization in healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989;19:55-62.
36. Holt PG, Reid M, Britten D, Sedgwick J, Bazin H. Suppression of IgE responses by passive antigen inhalation: dissociation of local and systemic immunity. Cell Immunol 1987;104:434-9.
37. Taylor G, Shivalkar E. Changes in nasal airways resistance on antigenic challenge in allergic rhinitis. Clin Allergy 1971;1:63-73.
38. Ciprandi G, Ricca V, Landi M, Passaiacqua G, Bagnasco M, Canonica GW. Allergen specific nasal challenge: response kinetic of cilnical and inflammatory events to rechallenge. Int Arch Allergy Immunol 1998;115:157-61.
39. Johansson SGO, Deuschl H, Zetterstrom O. Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitization of hay fever. Int Arch Allergy Appl Immunol 1979;60:447-60.
40. Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis: clinical response. J Allergy Clin Immunol 1981;68:33-40.
41. Welsh PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol 1981;67:237-42.
42. Schumacher MJ, Pain MCF. Intranasal immunotherapy with polymerized grass pollen allergens. Allergy 1981;37:241-5.
43. Georgitis JW, Reisman RE, Clayton WF, Muller U, Wypych J, Arbesman CE. Local nasal immunotherapy for grass allergic rhinitis. J Allergy Clin Immunol 1983;71:71-6.
44. Georgitis JW, Clayton WF, Wypich JI, Barde SH, Rasman RE. Further evaluation of local nasal immunotherapy with acqueous and allergoid grass extract. J Allergy Clin Immunol 1984;74:694-700.
45. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy for dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993;91:587-96.
46. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. Allergy 1992;47:318-23.
47. D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double blind placebo controlled trial of local nasal immunotherapy in allergic rhinitis to parietaria pollen. Clin Exp Allergy 1995;25:141-8.
48. Passalacqua G, Albano M, Ruffoni S, et al. Local nasal immunotherapy to parietaria: evidence of reduction of allergic inflammation. Am J Respir Crit Care Med 1995;152:461-6.
49. Andri L, Senna GE, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:1092-9.
50. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double blind study on 32 patients. J Allergy Clin Immunol 1996;97:37-41.
51. Cirla A, Sforza N, Roffi GP, et al. Preseasonal intranasal immunotherapy in birch-alder rhinitis: a double blind study. Allergy 1996;51:299-305.
52. Bardare M, Zaini C, Novembre E, Vierucci A. Local nasal immunotherapy with a powder extract for grass pollen rhinitis in pediatric ages: a controlled study. J Investig Allergol Clin Immunol 1996;97:34-41.
53. Bertoni M, Cosmi F, Bianchi I, Di Berardino L. Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy: results of preseasonal treatment in grass pollen rhinitis. Ann Allergy Asthma Immunol 1999;82:47-51.
54. Motta G, Passali D, De Vincentiis I, et al. A multicenter trial of specific local nasal immunotherapy. Laryngoscope 2000;110:132-9.
55. Pocobelli D, Del Bono A, Venuti L, Falagiani P, Venuti A. Nasal immunotherapy at constant dosage: a double blind placebo controlled study in grass allergic rhinoconjunctivitis. J Investig Allergol Clin Immunol 2001;11:79-88.
56. Marcucci F, Sensi LG, Caffarelli C, et al. Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy 2002;57:23-8.
57. Giannarini L, Maggi E. Decrease of allergen specific T cell response induced by nasal immunotherapy. Clin Exp Allergy 1998;28:404-12.
58. Bjorksten B. Local immunotherapy is not documented for clinical use. Allergy 1994;49:299-301.
59. Passalacqua G, Albano M, Pronzato C, Riccio A, Falagiani P, Canonica GW. Nasal immunotherapy to Parietaria: long term follow up of a double blind study. Clin Exp Allergy 1997;27:904-8.
60. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double blind study. Allergol Immunopathol 1990;18:277-84.
61. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
62. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double blind study. Allergol Immunopathol 1995;23:173-8.
63. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. J Investig Allergol Clin Immunol 1995;5:25-30.
64. Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. Pediatr Allergy Immunol 1997;8:21-7.
65. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998;53:493-8.
66. Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Investig Allergol Clin Immunol 1998;8:165-71.
67. Vourdas D, Syrigou E, Potamianou P, et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to alive tree pollen sensitization. Allergy 1998;53:662-71.
68. Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol 1998;26:234-40.
69. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998;351:629-32.
70. Passalacqua G, Albano M, Riccio AM, et al. Clinical and immunological effects of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999;104:964-8.
71. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999;54:249-60.
72. Purello D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immonotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinocon junctivitis, asthma or both. Allergy 1999;54:968-73.
73. Pradalier A, Basset D, Claudel A, et al. Sobiingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versos placebo in seasonal rhinitis. Allergy 1999;54:819-28.
74. La Rosa M, Ranno C, André C, et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425-32.
75. Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000;55:369-75.
76. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000;55:842-9.
77. Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:1142-7.
78. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica: a double blind study. Allergol Immunopathol (Madr) 2001;29:238-44.
79. Bahcecilier NN, Isik U, Barlan IB, Basaran N. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind. placebo-controlled study. Pediatr Pulmonol 2001;32:49-55.
80. Voltolini S, Modena P, Minale P, et al. Sublingual immunotherapy in tree pollen allergy: double blind, placebo controlled study with a biologically standardized extract of tree pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001;29:103-10.
81. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507-14.
82. Lombardi C, Gargioni S, Venturi S, Zoccali P, Canonica GW, Passalacqua G. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Investig Allergol Clin Immunol 2001;11:41-5.
83. Quirino T, Iemoli E, Siciliani E, Parmiani S. Sublingual vs injective immunotherapy in grass pollen allergic patients: a double blind double dummy study. Clin Exp Allergy 1996;26:1253-61.
84. Khinchi S, Poulsen LK, Carat F, André C, Malling HJ. Clinical efficacy of sublingual swallow and subcutaneous Immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen: a double blind double dummy placebo controlled study [abstract]. Allergy 2000;55(suppl 63):24.
85. Ongari S, Domeneghetti P, Parmiani S. Comparison among drugs, injective IT and sublingual IT in grass allergic patients. Allergy 1995;50:358.
86. Benrardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective VS sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol 1996;6:55-62.
87. Piazza I, Bizzarro N. Humoral response to subcutaneous, oral and nasal immunotherapy for allergic rhinitis due to dermatophagoides pteronyssinus. Ann Allergy 1993;71:461-9.
88. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485-90.
89. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-34.
90. Almangro E, Assensio O, Bartolomé JM, et al. Estudio multicentrico de farmacovigilancia de imunoterapia sublingual en pacientes alergicos. Allergol Immunopathol 1995;23:153-61.
91. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999;54:1110-3.
92. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001;56:889-92.
93. Lombardi C, Canonica GW, Passalacqua G. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000;55:677-8.
94. Marcucci F, Sensi L, Frati F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001;56:1091-5.
95. Tinkelman DG, Cole WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995;95:8-14.
96. Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. Allergy 1986;41:588-93.
97. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-78.
98. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461-72.
99. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000;55:522-30.
100. Durham SR, Till SJ. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-65.
101. Secrist H, Dekruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentrations and antigen presenting cell type. J Exp Med 1995;181:1081-9.
102. Varney VA, Hamid QA, Gaga M. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during late phase cutaneous response. J Clin Invest 1993;92:644-50.
103. Gabrielsson S, Soderlund A, Paulie S, et al. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 2001;56:293-300.
104. Benjaponpitak S, Oro A, Maguire P, et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999;103:468-75.
105. Durham SR, Walker SM, Varga EM, et al. Longterm clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999;341:468-75.
106. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-12.
107. Ariano R, Kroon H, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria: clinical and immunologic effects in a randomized, controlled trial. Allergy 1999;54:313-9.
108. Fanta C, Bohl B, Hirt W, et al. Systemic immunological changes induced by administration of grass pollen extract via oral mucosa during SLIT. Int Arch Allergy Immunol 1999;120:218-24.
109. Silvestri M, Spallarossa D, Battistini E, et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol 2002;12:52-9.
110. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune enkephalomyelitis. Science 1994;265:1237-40.
111. Holt PG, Vines J, Britten D. Sublingual allergen administration. 1. Selective suppression of IgE production in rats with high allergen doses. Clin Allergy 1988;18:229-34.
112. Mowart AM. The regulation of immune response to dietary proteins. Immunol Today 1987;8:93-6.
113. Miller A, Lider O, Roberts AB, Sporn MB. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune response by the release of TGFbeta following antigen specific triggering. Proc Natl Acad Sci U S A 1992;89:421-5.
114. Hasseus B, Dahlgren, Bergenholtz G, Jontell M. Antigen presenting capacity of Langerhans cells from rat oral epithelium. J Oral Pathol Med 1995;24:56-60.
115. VanWilsem EJ, Van Hoogsraten IM, Breve J, et al. Dendritic cells of the oral mucosa and the induction of oral tolerance: a local affair. Immunology 1994;93:128-32.
116. Macatonia SE, Hosken NA. Dendritic cells produce IL-12 and direct the development of TH1 cells from naive CD4+ T cells. J Immunol 1995;154:5071-9.
117. Tsitoure DC, DeKruyff RH, Lamb JR, Umetsu DT. Intranasal exposure to antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol 1999;163:2592-600.
118. Swarbrick ET, Stokes CR, Soothill JF. Absorption of antigens after oral immunisation and the simultaneous induction of specific tolerance. Gut 1979;20:121-3.
119. Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy 1988;43:469-75.
120. Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P judaica extracts. Allergy 1991;46:52-5.
121. Buckle FB, Cohen AB. Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrisnsic asthma. J Allergy Clin Immunol 1975;55:213-21.
122. Falagiani P, Mistrello G. Pharmacokinetics of allergens after local administration. Allergy 1997;52:17-21.
123. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the mayor Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997;100:121-9.
124. Bagnasco M, Passalacqua G, Villa G. Pharmacokinetics of an allergen and a monomeric allergoid for ommucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54-60.
125. Passalacqua G, Villa G, Altrinetti V, et al. Sublingual swallow or spit? Allergy 2001;56:578.
126. Frew AJ, White PJ. Sublingual immunotherapy. J Allergy Clin Immunol 1999;104:267-70.
127. Vervloet D, Birnbaum J, Laurent P, et al. Safety and clinical efficacy of rush sublingual cypress immunotherapy: preliminary results [abstract]. Allergy 2002;57(suppl 73):70.
128. Lower T, Hensy J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy 1993;70:480-2.
129. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-7.
130. Passalacqua G, Canonica GW. Alternative routes of immunotherapy: a review. J Investig Allergol Clin Immunol 1996;36:81-7.
131. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6.
132. Passalacqua G, Canonica GW. Long lasting efficacy of specific immunotherapy. Allergy 2002;57:275-6.
133. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long lasting effect of sublingual immunotherapy in children with asthma due to house dust mites: a ten-year prospective study. Clin Exp Allergy 2003;33:206-10.
134. Kagi MK, Wutrich B. Different methods of local allergen immunotherapy. Allergy 2002;57:379-88.
135. Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 2001;107:441-4.
136. Brown JL, Frew AJ. The efficacy of oromucosal immunotherapy in respiratory allergy. Clin Exp Allergy 2001;31:8-10.
137. Douglass J, O'Heir R. Specific allergen immunotherapy: time for alternatives? Clin Exp Allergy 2002;32:1-3.